Jeffrey Walch
Stock Analyst at Bernstein
(2.24)
# 3,129
Out of 5,043 analysts
30
Total ratings
46.2%
Success rate
3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Walch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $376 | $232.68 | +61.60% | 3 | Sep 25, 2026 | |
| BNTX BioNTech SE | Reiterated: Hold | $96 | $96.96 | -0.99% | 4 | Sep 25, 2026 | |
| INCY Incyte | Reiterated: Hold | $104 | $112.79 | -7.79% | 3 | Sep 25, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Hold | $229 | $218.42 | +4.84% | 3 | Sep 25, 2026 | |
| NBIX Neurocrine Biosciences | Reiterated: Buy | $218 | $142.44 | +53.05% | 4 | Sep 25, 2026 | |
| RVMD Revolution Medicines | Reiterated: Hold | $179 | $189.76 | -5.67% | 5 | Sep 25, 2026 | |
| SMMT Summit Therapeutics | Reiterated: Hold | $12 | $17.59 | -32.35% | 6 | Sep 25, 2026 | |
| VRTX Vertex Pharmaceuticals | Reiterated: Buy | $608 | $510.08 | +19.20% | 2 | Sep 25, 2026 |
Alnylam Pharmaceuticals
Sep 25, 2026
Reiterated: Buy
Price Target: $376
Current: $232.68
Upside: +61.60%
BioNTech SE
Sep 25, 2026
Reiterated: Hold
Price Target: $96
Current: $96.96
Upside: -0.99%
Incyte
Sep 25, 2026
Reiterated: Hold
Price Target: $104
Current: $112.79
Upside: -7.79%
Jazz Pharmaceuticals
Sep 25, 2026
Reiterated: Hold
Price Target: $229
Current: $218.42
Upside: +4.84%
Neurocrine Biosciences
Sep 25, 2026
Reiterated: Buy
Price Target: $218
Current: $142.44
Upside: +53.05%
Revolution Medicines
Sep 25, 2026
Reiterated: Hold
Price Target: $179
Current: $189.76
Upside: -5.67%
Summit Therapeutics
Sep 25, 2026
Reiterated: Hold
Price Target: $12
Current: $17.59
Upside: -32.35%
Vertex Pharmaceuticals
Sep 25, 2026
Reiterated: Buy
Price Target: $608
Current: $510.08
Upside: +19.20%